HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS(R) in Patients with MET Amplified Gastric Cancer

Source :: GlobeNewswire. July 27, 2021
Publication Year :: 2021
Abstract: HONG KONG, SHANGHAI, FLORHAM PARK, Jul 27, 2021 (GLOBE NEWSWIRE via COMTEX) -- HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13) and AstraZeneca PLC ('AstraZeneca') (LSE/STO/Nasdaq: AZN) have initiated a Phase II [...]

Subjects :: AstraZeneca PLC -- Product development
Tyrosine -- Product development
Cancer patients -- Care and treatment
Metastasis -- Care and treatment
Stomach cancer -- Care and treatment
Clinical trials
Cancer -- Care and treatment
Pharmaceutical industry -- Product development
Banking, finance and accounting industries
Business
Imfinzi (Medication) -- Product development
Tagrisso (Medication) -- Product development

Tools